Discipline and Rules-Based Execution in IDYA Response
This article analyzes Ideaya Biosciences Inc. (NASDAQ: IDYA), identifying a strong near-term sentiment with potential for mid-term neutrality leading to a long-term positive bias. It details an exceptional risk-reward setup targeting a 12.7% gain against 0.3% risk. The analysis includes three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for different time horizons.
IDEAYA Biosciences promotes Michael White to R&D president
IDEAYA Biosciences has promoted Dr. Michael White to President, Research and Development, from his previous role as Chief Scientific Officer, effective immediately. Dr. White has been with IDEAYA Biosciences since 2021 and previously served as Chief Scientific Officer and Head of Tumor Biology at Pfizer, Inc. The company specializes in developing targeted therapeutics for various cancer treatments.
IDEAYA Biosciences promotes Dr. Michael White to President of R&D to advance precision oncology pipeline.
IDEAYA Biosciences has promoted Dr. Michael White to President of Research and Development, effective September 28, 2026, recognizing his pivotal role in advancing the company's precision medicine oncology pipeline. This strategic leadership change is expected to accelerate the development of innovative therapies for various solid tumors. The announcement comes amidst a mixed performance in the health sector on Pluang, with some stocks rising and others falling.
IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development
IDEAYA Biosciences has promoted Dr. Michael White to President, Research and Development, effective September 28, 2026. Dr. White previously served as Chief Scientific Officer for five years, during which he was instrumental in advancing the company's precision medicine oncology pipeline. In his new role, Dr. White will continue to lead efforts to develop transformative therapies for various solid tumor indications, leveraging his extensive experience in oncology research and development.
Three new hires get options to buy 94,000 IDEAYA shares
IDEAYA Biosciences (IDYA) has granted stock options for 94,000 shares to three new employees on September 24, 2026. The options have an exercise price of $36.74, matching the closing price on the grant date, and will vest over four years. This grant falls under the 2023 Employment Inducement Incentive Award Plan and complies with Nasdaq Listing Rule 5635(c)(4).
IDEAYA Biosciences (Nasdaq:IDYA) - Stock Analysis
IDEAYA Biosciences (IDYA) is a precision medicine oncology company developing targeted therapeutics. The company is actively advancing multiple clinical programs, including a global Phase 3 trial for darovasertib in uveal melanoma and an FDA-backed Phase 3 trial plan for IDE849 in small cell lung cancer. Recent updates highlight partnerships with Servier, Genentech, and Roche, along with successful IND submissions and positive clinical data readouts across its pipeline.
IDEAYA Biosciences at Morgan Stanley conference: darovasertib leads push By Investing.com
IDEAYA Biosciences presented at the Morgan Stanley 24th Annual Global Healthcare Conference, highlighting its precision oncology strategy focused on genetically defined cancers. Darovasertib in uveal melanoma is the lead program, with NDA submission underway and a launch anticipated in early 2025. The company also detailed advancements in DLL3, MTAP/KRAS, PRMT5, and KAT6/7 programs, emphasizing a diversified pipeline and strong financial position to fund its clinical milestones.
IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma
IDEAYA Biosciences and Servier have dosed the first patient in OptimUM-11, a global Phase 3 registrational trial. This trial evaluates darovasertib in combination with crizotinib as an adjuvant therapy for patients with primary uveal melanoma who are at high risk of metastatic disease after local treatment. The aim is to address the significant unmet need for systemic treatment options to reduce metastatic recurrence in uveal melanoma.
Guggenheim raises Ideaya Biosciences stock price target on DLL3 data
Guggenheim has increased its price target for Ideaya Biosciences (NASDAQ:IDYA) to $57 from $54, maintaining a Buy rating, based on upcoming DLL3 data. The firm anticipates updated China Phase 1 data and initial global Phase 1 data for IDE849 in SCLC/NEC in the second half of 2026, leading to revised market assumptions for DLL3 and MTAP-del. Ideaya recently completed a public offering raising $345 million and initiated a Phase 1 clinical trial for IDE892, while Citizens also reiterated a Market Outperform rating.
IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer
IDEAYA Biosciences has announced a successful FDA Type C meeting regarding the Phase 3 registrational trial design for IDE849, a DLL3-targeting Topo-I-payload antibody drug conjugate, for extensive stage small cell lung cancer (ES-SCLC). The company plans to initiate a randomized Phase 3 trial by year-end 2026, aiming for potential accelerated and full approval. The trial will evaluate IDE849 monotherapy, with overall response rate as the primary endpoint for accelerated approval and overall survival for full approval.
IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) has announced an upcoming Investor R&D Day in London on November 16th, 2026, where management will discuss their MTAP/CDKN2A and KRAS development strategy in pancreatic cancer, including new preclinical data. Additionally, the company will participate in several investor conferences in September 2026, including the Wells Fargo 21st Annual Healthcare Conference, Cantor Global Healthcare Conference, Citi's 2026 Biopharma Back to School Conference, and Morgan Stanley 24th Annual Global Healthcare Conference. These events will feature fireside chats with Chairman and CEO Yujiro S. Hata and CFO Joshua Bleharski.
IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences
IDEAYA Biosciences (NASDAQ: IDYA) announced its upcoming Investor R&D Day in London on November 16, 2026, where management will discuss their MTAP/CDKN2A and KRAS development strategy in pancreatic cancer. The company also confirmed its participation in several investor conferences in September 2026, including events hosted by Wells Fargo, Cantor, Citi, and Morgan Stanley. Live audio webcasts and replays of these events will be available on the IDEAYA website.
IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences
IDEAYA Biosciences announced an upcoming Investor R&D Day in London on November 16, 2026, where they will discuss their MTAP/CDKN2A and KRAS development strategy, including new preclinical data. The company also announced participation in several investor conferences in September 2026, including events hosted by Wells Fargo, Cantor, Citi, and Morgan Stanley. These events will feature fireside chats with IDEAYA's Chairman and CEO, Yujiro S. Hata, and CFO, Joshua Bleharski.
IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer
IDEAYA Biosciences announced a successful FDA Type C meeting regarding the Phase 3 registrational trial design for its drug IDE849, a DLL3-targeting Topo-I-payload antibody drug conjugate, for extensive stage small cell lung cancer (ES-SCLC). The company plans to initiate the Phase 3 study by year-end 2026, aiming for potential accelerated approval based on overall response rate and full approval based on overall survival. IDEAYA will also provide clinical data updates for IDE849 in Q4 2026, including at ESMO 2026, and is exploring combinations for a potential first-line SCLC trial.
IDEAYA Biosciences advances commercial oncology with darovasertib success and $1.24B cash runway to 2030
IDEAYA Biosciences is transitioning into a commercial oncology company, bolstered by the positive phase 2 trial results of darovasertib, which demonstrated improved progression-free survival and supports its New Drug Application. The company boasts a strong financial position with $1.24 billion in cash, ensuring operations are funded through 2030, allowing for the development of multiple drug combinations and strategic collaborations. This robust standing positions IDEAYA for significant growth, especially with the anticipated approval of darovasertib for metastatic uveal melanoma.
Ideaya Biosciences stock hits 52-week high at 40.88 USD
Ideaya Biosciences (IDYA) stock reached a 52-week high of $40.88, reflecting a 61.06% increase over the past year, though InvestingPro analysis suggests it may be overvalued. The company recently initiated a Phase 1 clinical trial for a new cancer therapy and completed a public offering raising approximately $345 million. Analysts have maintained an "Market Outperform" rating with a price target of $45.00, indicating confidence in its growth potential.
Great Lakes Advisors LLC Makes New Investment in IDEAYA Biosciences, Inc. $IDYA
Great Lakes Advisors LLC has acquired a new stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) during the second quarter, purchasing 87,747 shares valued at approximately $3.27 million. This investment makes Great Lakes Advisors LLC an owner of about 0.10% of the company's stock. Other hedge funds have also adjusted their holdings in IDEAYA Biosciences, while the company's stock has seen positive movement despite missing recent earnings per share estimates.
IDEAYA Biosciences (IDYA) Is Up 5.2% After Genentech KRAS G12D Trial Collaboration News - Has The Bull Case Changed?
IDEAYA Biosciences has announced a clinical collaboration with Genentech to test its investigational MTA-cooperative PRMT5 inhibitor, IDE892, in combination with Genentech's KRAS G12D inhibitor GDC-7035 for a specific type of pancreatic cancer. This partnership is seen as external validation for IDEAYA's precision oncology platform and its focus on combination regimens in MTAP-deleted tumors. While the collaboration diversifies partnership support and strengthens confidence in IDEAYA's strategy, it also introduces another early-stage program that will require significant time and capital.
IDEAYA Biosciences (IDYA) Is Up 5.2% After Genentech KRAS G12D Trial Collaboration News - Has The Bull Case Changed?
IDEAYA Biosciences' stock rose 5.2% following news of a clinical collaboration with Genentech. The partnership involves testing IDEAYA's investigational MTA-cooperative PRMT5 inhibitor, IDE892, in combination with Genentech's KRAS G12D inhibitor GDC-7035 for a specific pancreatic cancer subgroup. This collaboration validates IDEAYA's precision oncology platform and combination strategy, though near-term catalysts remain focused on existing pipeline assets and addressing ongoing cash burn.
IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer
IDEAYA Biosciences has announced a clinical collaboration with Genentech to evaluate IDE892, an MTA-cooperative PRMT5 inhibitor, in combination with Genentech's KRAS G12D inhibitor, RG6620. This collaboration targets MTAP-deleted, KRAS G12D-mutant pancreatic ductal adenocarcinoma, aiming to address the high unmet medical need in this patient population. Genentech will sponsor the clinical trial, and the companies will retain commercial rights to their respective compounds.
Genentech doubles down on IDEAYA’s PRMT5 strategy with KRAS G12D combo
IDEAYA Biosciences and Genentech have announced a clinical collaboration to evaluate IDEAYA's IDE892, a PRMT5 inhibitor, in combination with Genentech's KRAS G12D inhibitor GDC-7035 for patients with MTAP-deleted and KRAS G12D-mutated pancreatic ductal adenocarcinoma. Genentech will fund the trial, with each company retaining commercial rights to their respective compounds. This collaboration marks IDEAYA's second with the Roche Group in 2026 for IDE892, building on a previous partnership for a pan-RAS inhibitor combination.
IDEAYA partners with Genentech on pancreatic cancer trial By Investing.com
IDEAYA Biosciences Inc. has announced a clinical collaboration with Genentech to evaluate IDE892 in combination with GDC-7035 for patients with pancreatic ductal adenocarcinoma who have both an MTAP-deletion and a KRAS G12D mutation. This trial targets a subset of pancreatic cancer patients who currently lack approved targeted treatment options. Genentech will sponsor the study, while IDEAYA will supply its investigational compound IDE892, with both companies retaining commercial rights to their respective therapies.
IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer
IDEAYA Biosciences has announced a clinical collaboration with Genentech to evaluate IDE892, their MTA-cooperative PRMT5 inhibitor, in combination with Genentech's KRAS G12D inhibitor (RG6620) for treating MTAP-deleted, KRAS G12D-mutant pancreatic cancer. Genentech will sponsor the trial, with joint governance overseeing the study, and IDEAYA will supply IDE892. This collaboration aims to address the high unmet medical need for patients with co-occurring MTAP deletions and KRAS G12D mutations in pancreatic ductal adenocarcinoma.
IDEAYA Biosciences (IDYA) Reports Second Quarter Results, Is The Valuation Still Justified?
IDEAYA Biosciences (IDYA) recently reported Q2 2026 results with $8.86 million in revenue and a net loss of $112.45 million, leading investors to re-evaluate the stock despite a strong 12-month performance. The company's current Price-to-Sales (P/S) ratio of 15.1x is considered expensive compared to industry averages and an estimated fair P/S of 4.3x, suggesting potential overvaluation based on revenue. However, a Discounted Cash Flow (DCF) model indicates the stock might be undervalued at its current price, presenting a mixed signal for investors.
IDEAYA Biosciences (IDYA) Reports Second Quarter Results, Is The Valuation Still Justified?
IDEAYA Biosciences (IDYA) recently reported its second-quarter 2026 results, showing increased revenue but wider net losses. The stock has seen significant momentum over the past year, prompting a re-evaluation of its valuation. While a Discounted Cash Flow model suggests undervaluation, its Price-to-Sales multiple indicates it is expensive compared to industry benchmarks, creating a mixed picture for investors.
Bank of America Corp DE Has $31.39 Million Stake in IDEAYA Biosciences, Inc. $IDYA
Bank of America Corp DE has increased its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 4.3% in the first quarter, holding over 942,000 shares valued at $31.39 million. Institutional investors and hedge funds collectively own 98.29% of the company. Despite reporting a quarterly loss, IDEAYA Biosciences saw significant revenue growth year-over-year, and analysts maintain a "Moderate Buy" consensus with an average price target of $50.12.
Walleye Capital LLC Buys Shares of 386,183 IDEAYA Biosciences, Inc. $IDYA
Walleye Capital LLC has acquired 386,183 shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) during the second quarter, a new stake valued at approximately $14.4 million. This purchase represents 0.44% of IDEAYA Biosciences. Despite a reported quarterly loss of $1.22 per share, institutional ownership of the company stands at 98.29%, and analysts maintain a "Moderate Buy" consensus with an average price target of $50.12.
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Average Rating of "Moderate Buy" from Brokerages
IDEAYA Biosciences (NASDAQ:IDYA) has received an average rating of "Moderate Buy" from sixteen brokerages, with an average 12-month price target of $50.13, significantly above its current share price of $36.30. The company's recent quarterly results showed revenue exceeding expectations but missed on earnings per share. Institutional ownership is very high at 98.29%, while insiders own 4.70% of the stock.
IDEAYA Biosciences (NASDAQ:IDYA) Rating Lowered to "Sell" at Wall Street Zen
Wall Street Zen downgraded IDEAYA Biosciences (NASDAQ:IDYA) from "hold" to "sell," despite the broader analyst consensus remaining a "Moderate Buy" with an average price target of $50.12. The company's shares opened at $36.30, and it recently reported a quarterly loss of $1.22 per share, missing estimates, though revenue increased significantly year-over-year. Institutional ownership is notably high at 98.29%, with some large firms establishing new positions, while a company accounting officer recently sold shares.
Baker Bros. Advisors (IDYA) reports 5.2% IDEAYA stake and capped warrants
Baker Bros. Advisors and its related entities have disclosed a 5.2% beneficial ownership stake in IDEAYA Biosciences, Inc. (IDYA), totaling 5,010,030 shares based on 96,375,637 shares outstanding as of June 30, 2026. The firm also holds prefunded warrants with a low exercise price but cannot currently exercise them due to an initial 4.99% ownership cap, which can be adjusted up to 19.99% after a 61-day waiting period. This disclosure was made via a SCHEDULE 13G SEC filing, indicating a passive investment.
IDEAYA Biosciences (IDYA) Short Interest & Short Float | Updated Aug 2026
IDEAYA Biosciences (IDYA) reported a short interest of 10.11 million shares as of July 31, 2026, marking a 5.64% increase from the previous period. This represents 12.08% of the public float and a short interest ratio of 13.2 days to cover. The article provides a detailed historical overview of IDYA's short interest data, comparing it to competitors and explaining key short-selling metrics.
How (IDYA) Movements Inform Risk Allocation Models
This article from Stock Traders Daily discusses how Ideaya Biosciences Inc. (NASDAQ: IDYA) movements inform risk allocation models. It highlights key findings such as a strong near-term sentiment possibly leading to a long-term positive bias, and an exceptional 49.4:1 risk-reward setup. The analysis provides institutional trading strategies including long, breakout, and short positions based on AI-generated signals for different time horizons.
How Investors Are Reacting To IDEAYA Biosciences (IDYA) Q2 Losses And IDE892 Trial Expansion
IDEAYA Biosciences reported Q2 2026 results with $8.86 million in revenue and a widened net loss of $112.45 million, or $1.22 per share. Despite the losses, the company advanced IDE892 into Part 2 monotherapy expansion for MTAP-deleted solid tumors, which is a positive development for its precision oncology pipeline. The investment narrative for IDEAYA hinges on clinical and regulatory milestones rather than near-term profitability, with the IDE892 expansion sharpening the long-term opportunity but also adding potential execution and financing risks due to rising development costs.
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $58
LifeSci Capital has reiterated its Buy rating for IDEAYA Biosciences (IDYA.US) and maintained its target price at $58. This indicates a continued positive outlook from the firm regarding the company's stock performance and potential.
IDEAYA Biosciences (IDYA) Stock Could Be Fully Valued After Trial Progress
IDEAYA Biosciences (IDYA) stock has delivered a 61.0% return over five years, but its current P/S ratio of 14.9x suggests it might be overvalued compared to the biotech industry average and a fair P/S of 4.3x implied by the model. While progress in its oncology pipeline could support future revenue, the stock's valuation appears to already price in a significant amount of future success, warranting caution for investors. The article emphasizes that the stock's future movement depends on whether current expectations are sustainable or if the valuation will normalize.
IDEAYA Biosciences, Inc. (IDYA) stock price, news, quote and history
This article provides a detailed financial overview of IDEAYA Biosciences, Inc. (IDYA), including its current stock price, historical data, and analyst ratings. It highlights the company's focus on developing targeted therapeutics for oncology and lists its key drug candidates and strategic alliances. The report also includes performance metrics, earnings trends, and valuation measures for IDYA.
The Bull Case For IDEAYA Biosciences (IDYA) Could Change Following Wider Loss And New Roche Partnership
IDEAYA Biosciences recently reported a wider Q2 2026 net loss of US$112.45 million, or US$1.22 per share, and an overall wider six-month loss compared to the previous year. Despite this, the company is advancing its precision oncology pipeline, initiating a monotherapy expansion for IDE892 and partnering with Roche for combination regimens in MTAP-deleted pancreatic cancer. The article suggests that while the company's valuation is high and it faces significant cash burn, these clinical advancements and partnerships could reshape its investment narrative, emphasizing the importance of trial progress over current earnings.
IDEAYA Biosciences 2Q 2026: Revenue $8.86M, EPS $(1.22) — 10-Q Summary
IDEAYA Biosciences reported its second-quarter 2026 results, showing collaboration revenue of $8.86 million and a net loss of $(112.45) million, or $(1.22) diluted EPS, due to increased R&D and commercial preparation. The company highlighted positive Phase 2/3 clinical trial results for darovasertib, with an NDA submission planned for H2 2026, and ongoing advancements in its pipeline. Financial highlights include a significant increase in revenue from the prior year and a worsening net loss.
IDEAYA BIOSCIENCES, INC. : LEERINK PARTNERS CUTS TARGET PRICE TO $31 FROM $37
LEERINK PARTNERS has cut its target price for IDEAYA BIOSCIENCES, INC. (IDYA.O) from $37 to $31. This information was reported by Reuters on August 5, 2026. The article does not provide further details or analysis regarding the reasons for the price target reduction.
IDEAYA BIOSCIENCES, INC. : LEERINK PARTNERS CUTS TARGET PRICE TO $31 FROM $37
Leerink Partners has decreased its target price for IDEAYA Biosciences, Inc. (IDYA.O) from $37 to $31. This adjustment was reported by Reuters on August 5, 2026, at 12:21 PM. The article provides this key financial action without further elaborating on the reasons behind the target price cut.
IDEAYA Biosciences (IDYA) Stock Faces Loss Pressure Despite Revenue Traction
IDEAYA Biosciences (IDYA) stock saw a modest increase after its Q2 2026 earnings report, which highlighted significant revenue growth but also widening net losses. While the company achieved substantial revenue traction and secured new funding, its increasing cash burn and lack of a clear path to profitability raise concerns for investors. The article suggests that despite positive developments in its pipeline, the high P/S ratio and deep losses could signal a value trap.
IDEAYA Biosciences (NASDAQ: IDYA) reports $1.24B cash and rising R&D spend
IDEAYA Biosciences reported Q2 2026 collaboration revenue of $8.9 million and a net loss of $112.5 million, with R&D expenses significantly increasing to $108.7 million for the quarter. The company strengthened its liquidity through a June 2026 follow-on offering and at-the-market sales, boosting cash, cash equivalents, and marketable securities to approximately $1.24 billion, which is expected to fund operations for at least 12 months. IDEAYA continues to heavily invest in its precision oncology pipeline, including darovasertib for uveal melanoma and multiple ADC and synthetic lethality programs.
Uveal melanoma trial reports 6.9 months progression-free vs. 3.1
IDEAYA Biosciences (IDYA) announced positive results from its registrational Phase 2/3 OptimUM-02 trial for darovasertib plus crizotinib in metastatic uveal melanoma, meeting its primary endpoint with a median progression-free survival (PFS) of 6.9 months compared to 3.1 months for the investigator's choice arm. The company is proceeding with an NDA filing under the FDA’s real-time oncology review program, targeting completion in the second half of 2026. IDEAYA also reported strong financial results for Q2 2026, ending the quarter with $1.24 billion in cash, cash equivalents, and marketable securities, extending its cash runway guidance into 2030.
IDEAYA Posts Q2 Loss as Cash Reaches $1.24 Billion
IDEAYA Biosciences (IDYA) reported a Q2 2026 net loss of $112.5 million ($1.22 per share) on collaboration revenue of $8.9 million, up from the prior quarter. The company announced its cash, cash equivalents, and marketable securities reached $1.24 billion, with cash runway guidance into 2030 remaining unchanged. IDEAYA also reported that its OptimUM-02 trial met its primary endpoint, leading to an NDA filing, and detailed upcoming data presentations and a new collaboration with Roche for a Phase 1 combination trial.
IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
IDEAYA Biosciences announced its second-quarter 2026 financial results and provided a business update. The company's registrational OptimUM-02 trial for darovasertib combination in metastatic uveal melanoma met its primary endpoint, with an NDA filing underway. IDEAYA also reported a strong financial position with approximately $1.24 billion in cash, cash equivalents, and marketable securities, projecting a cash runway into 2030.
IDEAYA Biosciences reports Q2 2026 net loss $112.5M; cash $1.24B after $323M offering
IDEAYA Biosciences reported a net loss of $112.5 million for Q2 2026, ending the period with $1.24 billion in cash, cash equivalents, and marketable securities after a $323 million public offering. The company's OptimUM-02 trial met its primary endpoint, leading to an NDA filing under the FDA RTOR program, and various other pipeline programs are advancing with several clinical data presentations and trial initiations planned.
IDEAYA Biosciences Q2 Loss Widens From Q1, Revenue Rises
IDEAYA Biosciences (IDYA) reported a wider loss of $1.22 per diluted share in Q2, compared to the previous quarter. Despite the increased loss, the company experienced a rise in revenue during the same period. This article provides a brief overview of IDEAYA's Q2 financial performance.
Earnings Flash (IDYA) IDEAYA Biosciences, Inc. Reports Q2 Revenue $8.9M, vs. FactSet Est of $8.0M
IDEAYA Biosciences, Inc. (IDYA) announced its Q2 revenue of $8.9 million, surpassing FactSet's estimate of $8.0 million. This news comes alongside other recent updates for the company, including Wedbush adjusting its price target to $60 and maintaining an Outperform rating, and the company's Q2 loss widening while revenue increased. IDEAYA Biosciences is a medicine oncology company focused on developing transformative therapies for cancer.
Dimensional Fund Advisors LP Increases Position in IDEAYA Biosciences, Inc. $IDYA
Dimensional Fund Advisors LP significantly increased its stake in IDEAYA Biosciences, Inc. (IDYA) by 42% in Q1, now holding 1.33 million shares valued at $44.4 million. Other institutional investors like State Street and Janus Henderson also boosted their positions, with institutional ownership reaching 98.29%. Despite a recent EPS miss, analysts maintain a "Moderate Buy" rating with a consensus target price of $50.25, while one insider recently sold shares.
IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences announced inducement grants of stock options to three new employees. These grants were approved by the Compensation Committee of the company's Board of Directors and are made under Nasdaq Listing Rule 5635(c)(4) as an inducement material to the employees entering into employment with IDEAYA. The stock options are exercisable for 31,500 shares of common stock, vest over four years, and have a ten-year term.
